Base Metals Investing Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Base Metals Investing Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
Base Metals Investing Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
Base Metals Investing Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research Special Conference on Pancreatic Cancer Research
Base Metals Investing Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
Base Metals Investing Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer
Base Metals Investing Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
Base Metals Investing Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
Base Metals Investing Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
Base Metals Investing Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
Base Metals Investing Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
